AdAlta (1AD) investor relations material

Growth strategy and business model

• Focuses on an "East to West" strategy, in-licensing advanced Asian cellular immunotherapies and adapting them for Western markets, targeting solid cancers which represent 90% of all cancers and are underserved by current therapies.

• Capital-efficient model leverages rapid Asian innovation, Australian manufacturing, and external capital, aiming for quick ROI and scalable pipeline expansion.

• Systematic asset selection process ensures access to highly differentiated, clinically validated products.

• Monetises additional assets in fibrosis and malaria through out-licensing and partnerships.

Lead asset: EW-001 CAR-T for mesothelioma

• EW-001 (formerly BZDS1901) is a next-generation, armoured CAR-T targeting mesothelin, showing complete responses in up to 20% of advanced mesothelioma patients.

• Demonstrates superior response rates and durability compared to current standards, with some patients achieving over two years of survival.

• Manufacturing process is rapid (<2 days), cost-effective, and does not rely on viral vectors, enhancing scalability and commercial appeal.

• Addresses a $4.2B market in mesothelioma, with potential in 10+ other cancers expressing mesothelin.

• Clinical data supports potential for accelerated regulatory pathways and high-value licensing deals.

Additional pipeline assets

• AD-214 is a first-in-class anti-fibrotic protein with Phase 1 completed, targeting large markets in chronic kidney disease ($10B) and idiopathic pulmonary fibrosis ($4.3B); available for partnering.

• WD-34 is a pan-species, high-potency anti-malarial antibody, offering long-acting prophylaxis and treatment, also available for out-licensing.

• Both assets are protected by strong IP and are positioned for value inflection through external partnerships.